Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

50.99USD
22 Apr 2014
Price Change (% chg)

$0.48 (+0.95%)
Prev Close
$50.51
Open
$50.54
Day's High
$51.47
Day's Low
$50.49
Volume
1,558,814
Avg. Vol
1,940,848
52-wk High
$57.49
52-wk Low
$39.18

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.45
Market Cap (Mil.): $83,693.68
Shares Outstanding (Mil.): 1,656.97
Dividend: 0.36
Yield (%): 2.85

Financials

  BMY.N Industry Sector
P/E (TTM): 32.65 32.71 32.86
EPS (TTM): 1.55 -- --
ROI: 9.61 19.60 18.86
ROE: 17.81 20.30 19.62
Search Stocks

Bristol-Myers hepatitis C treatment cures up to 90 percent: study

- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

10 Apr 2014

Bristol-Myers hepatitis C treatment cures up to 90 pct -study

April 10 - A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

10 Apr 2014

UPDATE 1-Bristol's Eliquis approved to prevent clots after hip, knee surgery

March 14 - U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.

14 Mar 2014

Bristol's Eliquis approved to prevent clots after hip, knee surgery

March 14 - U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.

14 Mar 2014

Bristol plans big lung cancer study, pairing immunotherapies

- Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company's intentions.

04 Mar 2014

Bristol plans big lung cancer study, pairing immunotherapies

March 4 - Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company's intentions.

04 Mar 2014

FDA approves Bristol-Myers' drug for rare fat disorder

- The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co's drug to treat rare and potentially fatal disorders involving loss of body fat.

26 Feb 2014

CORRECTED-UPDATE 1-FDA approves Bristol-Myers drug for rare body fat disorder

(Corrects throughout to change source to U.S. Food and Drug Administration from Bristol-Myers Squibb. The error also appeared in a previous version of the story)

25 Feb 2014

CORRECTED-FDA approves Bristol-Myers' drug for rare fat disorder

(Corrects source to U.S. Food and Drug Administration from Bristol-Myers Squibb)

25 Feb 2014

FDA approves Bristol-Myers drug for rare body fat disorder

- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat.

25 Feb 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $100.18 +0.18
Pfizer Inc. (PFE.N) $31.00 +0.14
Merck & Co., Inc. (MRK.N) $57.77 +0.52
Sanofi SA (SASY.PA) €77.23 +0.10
AstraZeneca plc (AZN.L) 4,035.00p +75.00
GlaxoSmithKline plc (GSK.L) 1,652.50p +12.50
Eli Lilly and Co (LLY.N) $60.03 -0.83

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks